A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
This clinical trial is looking at an experimental medicine called ABBV-319. It is designed for adults with specific types of blood cancer—such as diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukaemia—whose cancer has returned (relapsed) or stopped responding to prior treatments (refractory). Because this is an early-phase trial (Phase 1), it is one of the first times this drug is being given to people. The main goals are to check the safety of ABBV-319, find the best dose to use, and see what side effects it might cause. Doctors will also measure how the medicine moves through and leaves the body, and check if it helps shrink or control the cancer. The drug is given directly into a vein through a drip (intravenous infusion) at a hospital clinic.
At a glance
What is this study about?
Blood cancers such as diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia affect white blood cells called B-cells. In healthy bodies, these cells fight off infections. In people with these cancers, abnormal B-cells grow out of control. While existing NHS treatments work well for many people, sometimes the cancer returns after treatment (known as a relapse) or stops responding to standard therapies altogether (known as refractory cancer). When this happens, doctors need new, effective options to offer.
This study is testing an investigational drug called ABBV-319. It works by targeting cancer cells directly to help destroy them or stop them from multiplying. The drug is given straight into the bloodstream through a drip, known as an intravenous infusion.
Because this is a Phase 1 study, it represents one of the earliest steps in testing a new medicine in humans. The researchers want to understand how the human body handles the drug—how it is absorbed, broken down, and cleared away. Most importantly, the trial aims to find the safest possible dose that can help fight the cancer while keeping unwanted side effects as low as possible.
Key takeaways
- Tests an experimental drug called ABBV-319 for specific blood cancers.
- Aimed at adults whose cancer has returned or not responded to prior treatments.
- The primary goal is to find a safe dose and understand potential side effects.
- The drug is given by a drip directly into a vein at a specialist clinic.
- Participation is entirely voluntary, with close medical monitoring throughout.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with certain types of B-cell blood cancers. Specifically, this includes diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or chronic lymphocytic leukaemia (CLL).
To be considered, participants must have cancer that has either come back after earlier treatments or did not improve with standard therapies. Generally, volunteers need to be well enough to carry out everyday activities, have reasonably good kidney and liver function, and not be dealing with severe, uncontrolled infections.
People who are pregnant, breastfeeding, or have certain other active medical conditions may not be able to join. The hospital study team will carry out detailed blood tests and medical checks to decide whether taking part is safe for each individual.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with DLBCL, follicular lymphoma, or CLL.
- My cancer has returned or did not respond to previous standard treatments.
- I am well enough to attend regular hospital appointments and tests.
- I am willing to receive treatment through a vein at the clinic.
What does participation involve?
Taking part in this study involves regular visits to a specialist hospital clinic. Before starting, you will have health checks, including blood tests, physical exams, and scans, to confirm the trial is right for you. If you join, you will receive ABBV-319 as an intravenous drip into a vein. Because this is an early-stage study, you may need to stay at the clinic for several hours after your dose so doctors can carefully monitor your blood pressure, temperature, and overall wellbeing.
Throughout the study, you will have repeat blood tests, heart checks (ECGs), and imaging scans (such as CT or PET scans) to see how your body is handling the drug and whether the cancer is responding. The total time you spend in the trial depends on how well your body tolerates the medicine and whether it helps your condition. After treatment finishes, the team will continue to check on your health during follow-up visits or phone calls.
Potential risks and benefits
Locations (3)
- —UnverifiedItaly
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What is a Phase 1 clinical trial?
A Phase 1 trial is one of the first times a new medicine is tested in people. Its main purpose is to test safety, find the right dose, and check for side effects rather than prove how well it works.
How is the trial drug given?
ABBV-319 is given through a drip directly into a vein (an intravenous infusion) at the hospital clinic.
Will I have to pay for the trial treatment?
No, clinical trial medicines and study-related tests are provided free of charge. Some studies also help cover travel expenses to and from the hospital.
Can I leave the study if I change my mind?
Yes, you can withdraw from the trial at any time, for any reason. Your normal medical care will continue as usual.
Can I take my usual medicines during the trial?
Some medicines can interact with the trial drug. You must tell the study doctors about all prescriptions, over-the-counter drugs, and herbal supplements you take so they can check if they are safe.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.